Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood–Brain Barrier Crossing Ability

As a form of dementia, Alzheimer's disease (AD) suffers from no efficacious cure, yet AD treatment is still imperative, as it ameliorates the symptoms or prevents it from deteriorating or maintains the current status to the longest extent. The human brain is the most sensitive and complex organ...

Full description

Saved in:
Bibliographic Details
Published in:Advanced science 2024-10, Vol.11 (38), p.e2403473-n/a
Main Authors: Song, Qingting, Li, Junyou, Li, Ting, Li, Hung‐Wing
Format: Article
Language:English
Subjects:
Alzheimer's disease
Amino acids
blood–brain barrier
Contrast agents
Dementia
diagnosis and treatment
Disease
Drugs
Hypotheses
Inflammation
Kinases
Magnetic resonance imaging
Medical diagnosis
Nanomaterials
Nanotechnology
Neurotoxicity
Oxidative stress
Pathogenesis
Phosphorylation
Proteins
Review
Tomography
Toxicity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As a form of dementia, Alzheimer's disease (AD) suffers from no efficacious cure, yet AD treatment is still imperative, as it ameliorates the symptoms or prevents it from deteriorating or maintains the current status to the longest extent. The human brain is the most sensitive and complex organ in the body, which is protected by the blood–brain barrier (BBB). This yet induces the difficulty in curing AD as the drugs or nanomaterials that are much inhibited from reaching the lesion site. Thus, BBB crossing capability of drug delivery system remains a significant challenge in the development of neurological therapeutics. Fortunately, nano‐enabled delivery systems possess promising potential to achieve multifunctional diagnostics/therapeutics against various targets of AD owing to their intriguing advantages of nanocarriers, including easy multifunctionalization on surfaces, high surface‐to‐volume ratio with large payloads, and potential ability to cross the BBB, making them capable of conquering the limitations of conventional drug candidates. This review, which focuses on the BBB crossing ability of the multifunctional nanomaterials in AD diagnosis and treatment, will provide an insightful vision that is conducive to the development of AD‐related nanomaterials. Strategic design of different formulations of nanomaterials‐mediated molecule delivery systems with enhanced blood–brain barrier (BBB) crossing ability, as well as multiplexed mechanism of Alzheimer's disease (AD) for AD therapy and diagnosis is presented.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202403473